Does Ozempic Cause Eye Problems?

Summary: Yes. The Ozempic label warns that rapid blood sugar lowering can transiently worsen diabetic retinopathy, and a 2024 NAION signal has the FDA looking at sudden vision loss. Baseline and follow-up eye exams matter.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Yes. Ozempic can cause eye problems, and two of them are serious enough to take seriously before you start the drug. The first is worsening of pre-existing diabetic retinopathy, which is on the FDA label and traces back to the SUSTAIN-6 cardiovascular outcomes trial ^[1][2]. The second is non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that causes sudden, often permanent vision loss in one eye. NAION is not on the US label yet, but a 2024 study in JAMA Ophthalmology found semaglutide users had a four- to seven-fold higher risk than matched controls, and European regulators added it to product information in 2025 ^[3][4].

This page covers who is actually at risk, what symptoms to watch for, what monitoring to ask for, and what to do if your vision changes.

What the FDA label actually says

The Ozempic prescribing information lists "Diabetic Retinopathy Complications" as a warning. In the SUSTAIN-6 trial, which enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk, diabetic retinopathy complications happened in 3.0% of semaglutide patients versus 1.8% of placebo patients over two years. That is a 76% relative increase. Specific complications included vitreous hemorrhage, blindness, and the need for vitrectomy, photocoagulation, or intravitreal injection ^[1][2].

The label is direct: patients with a history of diabetic retinopathy should be monitored for progression. It does not tell people with retinopathy to avoid Ozempic, but it does flag the issue and put the monitoring burden on the prescribing team.

The mechanism is well understood and is not unique to Ozempic. Any treatment that rapidly lowers blood sugar from a chronically high baseline can transiently worsen retinopathy. The retina has adapted to elevated glucose. When glucose drops fast, the retinal microvasculature reacts before it readjusts, and existing lesions can progress. This same phenomenon happens with intensive insulin therapy and after bariatric surgery. It is the speed of the drop that drives the risk, not the drug itself.

NAION: the newer signal

NAION is a stroke of the optic nerve. Blood flow to the front of the optic nerve drops, the nerve fibers die, and vision is lost, usually in one eye, usually painlessly, often noticed on waking. Damage is permanent. There is no proven treatment.

The condition has known risk factors that have nothing to do with Ozempic: diabetes, high blood pressure, sleep apnea, high cholesterol, smoking, and a small "crowded" optic disc (a low cup-to-disc ratio, sometimes called a "disc at risk"). These are also the same risk factors common in people who get prescribed semaglutide, which is part of why the association has been hard to nail down.

The Hathaway et al. study in JAMA Ophthalmology, published July 2024, analyzed records from more than 16,000 patients seen at Mass Eye and Ear between 2017 and 2023. Among patients with type 2 diabetes, the 36-month cumulative incidence of NAION was 8.9% for semaglutide users versus 1.8% for non-semaglutide users. Among patients with overweight or obesity, it was 6.7% versus 0.8%. The hazard ratios were 4.28 for the diabetes cohort and 7.64 for the obesity cohort ^[3].

Those numbers look alarming and the absolute incidence in that study was unusually high, likely because the study was conducted at a tertiary neuro-ophthalmology referral center where NAION cases concentrate. Later, larger database studies have produced more modest estimates. A 2025 analysis covering roughly 37 million adults with type 2 diabetes pegged the relative risk at about 2.19. The European Medicines Agency reviewed the evidence in June 2025 and classified NAION as a "very rare" side effect, with an absolute frequency of up to 1 in 10,000 patients, and required Novo Nordisk to add the risk to European product information ^[4].

Blurred vision when you start

This is the most common eye-related complaint and it is usually not NAION or retinopathy progression. It is the lens of your eye changing shape as your blood sugar drops.

The lens absorbs glucose and water from the aqueous humor. When blood sugar is chronically high, the lens swells. When semaglutide brings glucose down over a few weeks, the lens shrinks and your refractive error shifts. Reading glasses that worked last month no longer do. Distance vision blurs. The change can go either way, hyperopic or myopic, depending on the baseline.

Per the American Academy of Ophthalmology, this typically resolves within three to four months as the lens stabilizes at the new glucose level ^[5]. Older patients take longer because the aging lens is less flexible. Do not buy new glasses during the titration window. Wait until your vision stabilizes, then get refracted. Otherwise you will be back at the optometrist in eight weeks.

Who is actually at risk

The patient profiles where Ozempic eye risks become meaningful, rather than theoretical, are specific.

Highest risk for retinopathy worsening:

• Pre-existing diabetic retinopathy, especially moderate to severe non-proliferative or proliferative disease.
• HbA1c above 9% at baseline. The bigger the planned glucose drop, the bigger the transient worsening risk.
• Recent rapid HbA1c reduction from any cause (new insulin, bariatric surgery, dietary intervention).
• Long duration of diabetes with poor control.
• Concurrent use of other glucose-lowering medications that will compound the speed of the drop.

Highest risk for NAION:

• Previous NAION in the fellow eye (recurrence in the same eye is rare, but the other eye is at high risk).
• Small or crowded optic disc (cup-to-disc ratio at or below 0.3). An ophthalmologist can measure this on a routine exam.
• Diabetes, hypertension, sleep apnea, or significant cardiovascular disease.
• Use of PDE5 inhibitors (sildenafil, tadalafil) on top of other risk factors.
• Age over 50.

The absolute risk in any one patient is still small. The European regulator's "up to 1 in 10,000" estimate covers the average semaglutide user. People stacking multiple risk factors are not average.

Symptoms that need an eye exam this week

Symptoms that should send you to an eye doctor without waiting for your next regular appointment:

• A dark or gray patch in part of your visual field, especially the lower half, in one eye.
• Sudden blurring that does not clear with blinking.
• Loss of side vision in one eye.
• A "smudge" over part of one eye that does not move when you move your eye.
• Loss of color saturation in one eye (colors look washed out compared to the other side).
• New floaters in large numbers, or flashes of light, which can signal retinal complications.
• Painless vision dimming that comes and goes ("brownout").

Symptoms that are common, almost always benign, and usually resolve within the first three to four months:

• Mild bilateral blurring that affects reading or distance similarly.
• A noticeable shift in your eyeglass prescription.
• Eyes feeling slightly drier than usual (semaglutide can mildly contribute to dehydration if you have GI side effects).

The pattern that matters is unilateral and sudden versus bilateral and gradual. Sudden in one eye is a red flag. Gradual and in both eyes is usually the lens adjusting.

Monitoring: what to ask for

A reasonable monitoring plan, drawn from the AAO commentary and the standard of care for high-risk patients ^[5]:

The baseline matters most. If something changes, the doctor needs a previous image to compare against. Optical coherence tomography (OCT) of the optic nerve and retina is the standard tool. Most ophthalmology and many optometry offices have it.

If your prescriber did not mention eye monitoring and you have type 2 diabetes or any of the NAION risk factors, raise it yourself. The conversation goes: "I am starting Ozempic. Should I have a baseline eye exam, and how often should I be checked?"

What to do if symptoms appear

The action depends on the symptom and the timing.

Sudden vision loss in one eye, any duration: same-day eye emergency evaluation. If your ophthalmologist cannot see you that day, go to a hospital with an ophthalmology service. Do not stop Ozempic on your own before the evaluation. The decision to continue or discontinue depends on what is found, and stopping the drug will not reverse NAION damage that has already happened.

Persistent unilateral blurring or visual field defect: contact your eye doctor within a few days. Bring a list of all your medications and your most recent HbA1c.

Bilateral mild blurring in the first few months: this is almost certainly the lens adjusting. Hold off on new glasses, mention it at your next regular appointment, and report to your prescriber if it does not start improving by month four.

Worsening of known diabetic retinopathy on a scheduled exam: your retina specialist will recommend treatment, which may include anti-VEGF injections, focal laser, or panretinal photocoagulation. Continuing or pausing Ozempic is a joint decision between the endocrinologist and the retina specialist. In most cases the cardiovascular and renal benefits of semaglutide outweigh the retinopathy risk if treatment is in place.

Wegovy, Rybelsus, and the rest

Wegovy is the same molecule as Ozempic, just at higher doses for weight management. The eye risk profile is the same. The NAION signal in the JAMA Ophthalmology study was actually stronger in the weight-loss cohort than in the diabetes cohort, which suggests dose and the speed of metabolic change both matter.

Rybelsus is oral semaglutide. Same molecule, same risks, same warnings. The diabetic retinopathy warning is on the Rybelsus label too.

Tirzepatide (Mounjaro, Zepbound) is a different drug, but the 2025 Katz et al. case series in JAMA Ophthalmology described NAION and other vision events in patients on both semaglutide and tirzepatide. The mechanism is presumed to be the same: rapid metabolic change driving optic nerve and retinal stress.

If you have glaucoma, the picture is actually more favorable. Several observational analyses have suggested GLP-1 receptor agonists may modestly reduce glaucoma risk or progression, possibly through anti-inflammatory effects on retinal ganglion cells. The data are early and not strong enough to call protective, but glaucoma is not a contraindication to Wegovy or Ozempic.

The bottom line on continuing versus stopping

For most people on Ozempic, the eye benefits of better long-term blood sugar control outweigh the transient risks. Improved glycemic control over years reduces diabetic retinopathy progression, not the other way around. The risk window is the titration period and the first year, especially in patients starting from poor control. SUSTAIN-6 showed retinopathy worsening within the first year, then attenuation ^[2].

NAION is uncommon in absolute terms even at the higher end of the risk estimates. For a 55-year-old with type 2 diabetes who needs better glucose control and weight loss, the cardiovascular and renal benefits of semaglutide are substantial and well documented. Stopping Ozempic out of fear of a 1-in-10,000 event would trade a defined long-term benefit for protection against a rare short-term harm.

That calculus changes if you have already had NAION in one eye, or if you have a known disc-at-risk plus uncontrolled hypertension plus sleep apnea, or if your retinopathy is already moderate and progressing. Those conversations belong with an ophthalmologist and your prescribing physician, not with an internet search.

Common questions about Ozempic and vision

Does Ozempic cause blindness?

Permanent vision loss from Ozempic is rare. The main mechanism is NAION, which the European regulator classifies as affecting up to 1 in 10,000 users. Diabetic retinopathy worsening is more common but usually manageable with eye care.

Does blurred vision from Ozempic go away?

Yes, in most cases. Blurred vision in the first weeks comes from the eye lens adjusting to lower blood sugar, and typically resolves within three to four months. Do not buy new glasses until your vision stabilizes.

Can semaglutide cause eye problems if I do not have diabetes?

The retinopathy risk requires pre-existing diabetic eye disease, so weight-loss-only users are not at meaningful retinopathy risk. The NAION signal was actually higher in the weight-loss cohort in the JAMA Ophthalmology study, so the risk is not zero.

Does Wegovy cause blindness?

The risk profile is identical to Ozempic since both are semaglutide. The NAION signal was somewhat stronger in weight-loss patients in the available data, though absolute incidence remains low.

Should I get an eye exam before starting Ozempic?

If you have type 2 diabetes, yes, get a dilated exam first. If you have any NAION risk factors (previous NAION, small optic disc, sleep apnea, hypertension), yes. If you are otherwise healthy and using Ozempic for weight loss, a baseline exam is reasonable but not mandatory.

Can you take Wegovy if you have glaucoma?

Yes. Glaucoma is not a contraindication. Some early data suggest GLP-1 drugs may even be mildly protective against glaucoma progression, though the evidence is preliminary.

What is the connection between semaglutide and diabetic retinopathy?

Rapid blood sugar lowering can transiently worsen pre-existing diabetic retinopathy. This is on the FDA Ozempic label and was first identified in the SUSTAIN-6 trial. The worsening usually stabilizes after the first year, and long-term glucose control protects the retina.

Are there other eye conditions linked to Ozempic?

Case reports describe papillitis (optic nerve swelling), paracentral acute middle maculopathy, and possible worsening of neovascular age-related macular degeneration. These are uncommon and the causal link is not established. Sudden vision changes warrant prompt evaluation regardless of the suspected diagnosis.

Does the FDA require a NAION warning on Ozempic?

Not as of early 2026. The European Medicines Agency added NAION to product information in 2025, and the WHO issued an alert the same year. The FDA continues to review the data.

How fast should I expect vision symptoms after starting Ozempic?

Lens-related blurring typically appears within the first few weeks as blood sugar drops. Retinopathy progression usually shows up in the first year. NAION, when it occurs, has happened most often in the first 12 months of treatment in published series, but later cases have been reported.

What this article does not cover

This page is a clinical overview of Ozempic eye risks. It is not legal advice on the active NAION litigation, which is moving through state and federal courts as of 2026. It is not a substitute for an ophthalmologist's evaluation of your specific eyes. The math on dosing, the comparison with tirzepatide, and the broader semaglutide side effect picture each have their own dedicated pages on this site. Use the sidebar to find them.